Vertex Advances Pove to Phase III at 80 mg Q4W; JOURNAVX Access Focus

Pove in membranous: what signals/data supported moving to Phase III (80 mg Q4W) and what it implies

1) The decision was driven by DSMB review of Phase II safety + biomarker read-through (with efficacy unblinded only to the DSMB)

• Vertex moved Pove in membranous nephropathy (pMN) from a seamless Phase II/III design to Phase III with an 80 mg subcutaneous every 4 weeks dose after the IDMC completed its review and selected the Phase III dose. ¹
• Management explicitly stated that the DSMB (IDMC) based its decision on the Phase II portion, and that Vertex does not have access to the unblinded efficacy data for PLA2R (the biomarker equivalent to IgA1 in IgAN), while the DSMB had full access to safety results. ²
• Therefore, the “signal” supporting dose selection is best characterized as: DSMB/IDMC access to Phase II safety and their view of the Phase II/IIb information on PLA2R, even though Vertex itself did not disclose unblinded efficacy access in the excerpt. ²

2) The 80 mg dose selection aligns with the RUBY-3 pattern in PLA2R reduction

• Vertex noted it is “not surprising” the DSMB picked 80 mg, referencing RUBY-3, where 80 mg showed a “very nice reduction in PLA2R.” ²
• The dosing decision thus appears to be a consistent biomarker efficacy/safety dose selection rationale, with PLA2R serving as the key biomarker readout for membranous activity. ²

3) What’s already “locked in” operationally for Phase III

• Vertex said the Phase III portion was initiated last quarter, and the Phase II portion is complete. ¹
• The Phase III study is described as well on its Phase III portion, with enrollment/completion still ahead. ²

Bottom line (Pove pMN): Based on the excerpt, the move to Phase III at 80 mg Q4W was supported by IDMC/DSMB dose selection after Phase II review, with PLA2R reduction patterns consistent with RUBY-3 as the efficacy signal, and full DSMB access to safety since Vertex lacks unblinded efficacy access for PLA2R. ²¹

---

JOURNAVX in acute pain: key next steps for formulary access, payer dynamics, and co-pay considerations

1) Formulary/hospital access: widening pathways via hospitals/IDNs and continuing education

• Vertex reported JOURNAVX is now on ~1,400 hospital pathways and 130 IDN pathways via formulary, protocol, or order sets. ³
• They also emphasized ongoing work to ensure access is “seamless,” particularly where quantity limits and related controls exist in formularies. ³

Implication: Even with broad pathway penetration, access friction remains at the formulary level (e.g., quantity limits and administrative requirements), and Vertex’s stated plan is continued navigation/support and physician education. ³

2) Payer dynamics: expanding Medicare Part D and describing coverage vs. restrictions

• Vertex secured 2 additional Medicare Part D plans covering JOURNAVX starting July 1. ⁴
• With these additions, 3 of the big 4 Medicare Part D plans provide covered access alongside 3 large commercial PBMs. ³
• Management reported ~260 million lives covered for JOURNAVX, and said this was ahead of the July 1 Part D additions. ⁴
• They further broke coverage down into ~180 million lives with “unrestricted access” and ~60 million lives yet to be covered out of ~320 million possible. ³
• They characterized remaining restrictions as “usually very minor,” including a 14-day quantity limit or prior authorization to indication, which can trigger the need for support programs. ⁵

Implication: Payer dynamics are not binary (covered vs. not covered). The meaningful “next step” is converting restricted coverage into operationally usable access—especially around quantity-limit and PA controls—while extending coverage to the remaining populations not yet covered. ³⁵

3) Co-pay considerations: rely on PSP while navigating restrictions; educate to reduce PSP trigger frequency

• Vertex explicitly discussed that rapid prescription growth is causing greater use of the PSP program than forecast because unrestricted payer access and physician education are catching up. ⁵
• They described the practical co-pay/access issue as patients needing help when restrictions exist (e.g., quantity limits or PAs), and stated they expect PSP to be triggered less frequently as they continue educating physicians and office staff on navigation of quantity limits and prior authorizations. ⁵
• They said that they would maintain the PSP program to ensure patients can still get JOURNAVX while working to secure broader coverage. ³

Implication for co-pay considerations (as framed in the excerpt): Vertex treats PSP as the near-term “bridge” to ensure patients obtain therapy when payer restrictions create administrative hurdles; the strategy to reduce those PSP touchpoints is education and smoother prescriber office workflows, not simply further payer coverage claims. ³⁵

4) Timing/access execution: “highly time-sensitive” delivery and wholesalers/retail channel normalization

• Vertex emphasized its goal for a seamless prescribing experience in a market where delivery is highly time-sensitive. ³
• They also noted that acute product launches can show quarterly volatility in inventory build/drawdown as wholesalers/retail patterns normalize to formulary adoption, physician awareness, and seasonality. ⁶

Implication: Even if payer coverage is improving, operational access depends on formulary adoption translating into consistent channel buying patterns, which influences supply/inventory management and, indirectly, patient access continuity. ⁶

5) Programmatic next steps Vertex highlights for sustained growth and access completion

Vertex’s “critical markers” for building a long-term pain franchise include payer coverage breadth and addition to hospital and IDN pathways, with prescription growth and prescriber breadth/depth as parallel drivers. ⁶

• Short-term execution focus in acute pain is explicitly stated as making sure reimbursement contracts are done and access is secured, and that this has been the top priority (“hyper-focused on acute pain”). ⁷
• They also reiterate they have “more work” to secure “final elements of access,” including helping patients whose physicians face quantity limits navigate them so patients can secure access. ⁴³

---

Integrated takeaway: what to watch as “next steps” for JOURNAVX

1. Complete conversion of restricted coverage to frictionless access: reduce the operational impact of quantity limits (e.g., 14-day) and prior authorization via education and navigation—so PSP is used less frequently over time. ⁵
2. Continue payer expansion momentum: add remaining populations toward the total possible coverage base (they cite ~260M covered out of ~320M, with ~180M unrestricted). ³
3. Operationalize formulary/hospital pathway adoption: keep scaling hospital/IDN pathways and ensure the “highly time-sensitive” delivery model remains smooth. ³
4. Manage launch-related volatility as formulary adoption changes channel buying patterns. ⁶

All of the above is consistent with Vertex’s stated emphasis that acute pain progress is proceeding through formularies/payer coverage and access logistics, with PSP and prescriber-office education serving as the near-term mechanism to manage co-pay/access friction while the broader payer environment catches up. ³⁵